KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Amortization of Deferred Charges: 2009-2025

Historic Amortization of Deferred Charges for Biomarin Pharmaceutical (BMRN) over the last 13 years, with Sep 2025 value amounting to $649,000.

  • Biomarin Pharmaceutical's Amortization of Deferred Charges fell 9.61% to $649,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year decrease of 28.73%. This contributed to the annual value of $3.4 million for FY2024, which is 19.79% down from last year.
  • As of Q3 2025, Biomarin Pharmaceutical's Amortization of Deferred Charges stood at $649,000, which was down 1.67% from $660,000 recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Amortization of Deferred Charges registered a high of $1.1 million during Q3 2023, and its lowest value of $649,000 during Q3 2025.
  • In the last 3 years, Biomarin Pharmaceutical's Amortization of Deferred Charges had a median value of $990,000 in 2024 and averaged $865,091.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Amortization of Deferred Charges plummeted by 80.28% in 2021, and later climbed by 11.00% in 2023.
  • Quarterly analysis of 5 years shows Biomarin Pharmaceutical's Amortization of Deferred Charges stood at $1.0 million in 2021, then decreased by 0.39% to $1.0 million in 2022, then fell by 3.70% to $990,000 in 2023, then plummeted by 33.33% to $660,000 in 2024, then dropped by 9.61% to $649,000 in 2025.
  • Its last three reported values are $649,000 in Q3 2025, $660,000 for Q2 2025, and $660,000 during Q1 2025.